References

oncotomsk

Сибирский онкологический журнал

Siberian journal of oncology

1814-48612312-3168

Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences

10.21294/1814-4861-2022-21-4-124-136

oncotomsk-2248

Research Article

ОБЗОРЫ

REVIEWS

Поляризация макрофагов: механизмы, маркеры и факторы индукции

Polarization of macrophages: mechanisms, markers and factors of induction

https://orcid.org/0000-0002-5121-2535

Федоров

А. А.

Fedorov

A. A.

Федоров Антон Андреевич - аспирант лаборатории молекулярной онкологии и иммунологии, младший научный сотрудник лаборатории биологии опухолевой прогрессии.

634009, Томск, пер. Кооперативный, 5.

SPIN-код: 1315-8100. Researcher ID (WOS): AAG-8911-2020. Author ID (Scopus): 57211136209.

Anton A. Fedorov - Postgraduate, Laboratory of Molecular Oncology and Immunology, Junior Researcher of the Laboratory of Cancer Progression Biology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.

5, Kooperativny St., 634050, Tomsk.

Researcher ID (WOS): AAG-8911-2020. Author ID (Scopus): 57211136209.

anton.fedorov.2014@mail.ru

https://orcid.org/0000-0003-1205-5976

Ермак

Н. А.

Ermak

N. A.

Ермак Никита Андреевич - студент 6-го курса.

634050, Томск, Московский тракт, 2.

Nikita A. Ermak - 6th year student, Siberian State Medical University of the Ministry of Health of Russia.

2, Moskovsky trakt, Tomsk, 634050.

https://orcid.org/0000-0002-7283-0092

Геращенко

Т. С.

Gerashchenko

T. S.

Геращенко Татьяна Сергеевна - кандидат медицинских наук, научный сотрудник лаборатории биологии опухолевой прогрессии.

634009, Томск, пер. Кооперативный, 5.

SPIN-код: 7900-9700. Researcher ID (WOS): A-7011-2014. Author ID (Scopus): 55948412900.

Tatiana S. Gerashchenko - PhD, Researcher of the Laboratory of Cancer Progression Biology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.

5, Kooperativny St., 634050, Tomsk.

Researcher ID (WOS): A-7011-2014. Author ID (Scopus): 55948412900.

https://orcid.org/0000-0002-5674-0177

Топольницкий

Е. Б.

Topolnitskii

E. B.

Топольницкий Евгений Богданович - доктор медицинских наук, профессор кафедры хирургии с курсом мобилизационной подготовки и медицины катастроф, СибГМУ Минздрава России; заведующий хирургическим торакальным отделением, Томская ОКБ.

634050, Томск, Московский тракт, 2; 634063, Томск, ул. Ивана Черных, 96.

SPIN-код: 6744-9541. Researcher ID (WOS): T-5818-2018. Author ID (Scopus): 35197267200.

Evgenii B. Topolnitskii - MD, Professor of the Department of Surgery with a Course of Mobilization Training and Disaster Medicine, Siberian State Medical University of the Ministry of Health of Russia; Head of the Department Thoracic Surgery, Tomsk Regional Clinical Hospital.

2, Moskovsky trakt, Tomsk, 634050; 96, Ivana Chernykh St., 634063, Tomsk.

Researcher ID (WOS): T-5818-2018. Author ID (Scopus): 35197267200.

https://orcid.org/0000-0002-0011-8370

Шефер

Н. А.

Shefer

N. A.

Шефер Николай Анатольевич - кандидат медицинских наук, врач-онколог.

634009, Томск, пр. Ленина, 115.

SPIN-код: 3662-7399. Author ID (Scopus): 57211683932.

Nikolay A. Shefer - MD, PhD, Oncologist of the Surgery Department, Tomsk Regional Oncology Center.

115, Lenina Ave., 634009, Tomsk.

Author ID (Scopus): 57211683932.

https://orcid.org/0000-0003-4980-8986

Родионов

Е. О.

Rodionov

E. O.

Родионов Евгений Олегович - кандидат медицинских наук, старший научный сотрудник отделения торакальной онкологии, Научно-исследовательский институт онкологии, Томский НИМЦ РАН; ассистент кафедры онкологии, СибГМУ Минздрава России.

634009, Томск, пер. Кооперативный, 5; 634050, Томск, Московский тракт, 2.

SPIN-код: 7650-2129. Researcher ID (WOS): B-7280-2017. Author ID (Scopus): 57189622130.

Evgenii O. Rodionov - MD, PhD, Senior Researcher of the Thoracic Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Assistant of the Department of Oncology, Siberian State Medical University of the Ministry of Health of Russia.

5, Kooperativny St., 634050, Tomsk; 2, Moskovsky trakt, Tomsk, 634050.

Researcher ID (WOS): B-7280-2017. Author ID (Scopus): 57189622130.

https://orcid.org/0000-0003-0601-2240

Стахеева

М. Н.

Stakheyeva

M. N.

Стахеева Марина Николаевна - доктор медицинских наук, ведущий научный сотрудник лаборатории молекулярной онкологии и иммунологии.

634009, Томск, пер. Кооперативный, 5.

SPIN-код: 7804-0361. Researcher ID (WOS): C-6184-2012. Author ID (Scopus): 6505941716.

Marina N. Stakheyeva - MD, DSc, Leading Researcher of the Laboratory of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.

5, Kooperativny St., 634050, Tomsk.

Researcher ID (WOS): C-6184-2012. Author ID (Scopus): 6505941716.

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation

Сибирский государственный медицинский университет Минздрава РоссииРоссияSiberian State Medical University of the Ministry of Health of RussiaRussian Federation

Сибирский государственный медицинский университет Минздрава России; Томская областная клиническая больницаРоссияSiberian State Medical University of the Ministry of Health of Russia; Tomsk Regional Clinical HospitalRussian Federation

Томский областной онкологический диспансерРоссияTomsk Regional Oncology CenterRussian Federation

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; Сибирский государственный медицинский университет Минздрава РоссииРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University of the Ministry of Health of RussiaRussian Federation

2022

03092022

214124136

2022

Федоров А.А., Ермак Н.А., Геращенко Т.С., Топольницкий Е.Б., Шефер Н.А., Родионов Е.О., Стахеева М.Н.

Fedorov A.A., Ermak N.A., Gerashchenko T.S., Topolnitskii E.B., Shefer N.A., Rodionov E.O., Stakheyeva M.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.siboncoj.ru/jour/article/view/2248

Макрофаги являются ключевыми компонентами врожденной иммунной системы. Вариативность участия макрофагов в различных патологических процессах, определяемая их функциональной поляризацией, открывает широкую перспективу для модуляции их функционального профиля для использования в терапевтических целях. Цель исследования – предоставить современные данные о процессе поляризации макрофагов, механизмах его регуляции, маркерах поляризации и факторах индукции. Материал и методы. Проведен поиск доступных литературных источников, опубликованных в базах данных Web of Science, Scopus и др. Найдено более 160 источников, посвященных изучению процесса поляризации макрофагов, из которых 121 включен в данный обзор. Результаты. В обзоре представлены данные о молекулярных механизмах и генных сигнатурах, ассоциированных с М1- и М2- поляризацией макрофагов, информация о метаболических, фенотипических признаках и цитокиновом профиле М1- и М2-макрофагов, а также освещены данные о факторах поляризации и мишенях их воздействия. Заключение. Представленные в обзоре сведения могут послужить информационной базой для разработки экспериментальных и клинических подходов для редактирования функционального профиля макрофагов с целью управления патологическими процессами с их участием.

Macrophages are key components of the innate immune system. The variability of the macrophage’s participation in tumor progression, determined by their functional polarization, opens up a wide prospect for modulating their functional profile, primarily in the direction of increasing antitumor activity. The purpose of the study was to provide up-to-date data on the process of macrophage polarization, mechanisms of its regulation, polarization markers and induction factors. Material and methods. A search was made for available literature sources published in Web of Science, Scopus and other databases. more than 160 sources devoted to the study of the process of macrophage polarization were found, of which 121 were included in this review. Results. This review presents data on the molecular mechanisms and gene signatures associated with M1 and M2 polarization of macrophages. We displayed information on metabolic, phenotypic characteristics and cytokine profile of M1- and M2-macrophages, as well as highlighted data on polarization factors and targets of their action. Conclusion. The information presented in the review can serve as an information base for the development of experimental and clinical approaches for editing the functional profile of macrophages in order to control their involvement in various pathological processes.

макрофагипластичностьфакторы поляризация

macrophagesplasticitypolarization factors

Обзор выполнен при финансовой поддержке гранта РФФИ 20-315-90055.

The study was funded by RFBR, project number 20-315-90055.

References1

Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496(7446): 445–55. doi: 10.1038/nature12034.

Ma W.-T., Gao F., Gu K., Chen D.-K. The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review. Front Immunol. 2019; 10(1140). doi: 10.3389/fimmu.2019.01140.

Sica A., Erreni M., Allavena P., Porta C. Macrophage polarization in pathology. Cell Mol Life Sci. 2015; 72(21): 4111–26. doi: 10.1007/s00018-015-1995-y.

Das A., Sinha M., Datta S., Abas M., Chaffee S., Sen C.K., Roy S. Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol. 2015; 185(10): 2596–606. doi: 10.1016/j.ajpath.2015.06.001.

Cheng Z., Zhang D., Gong B., Wang P., Liu F. CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer. Oncotarget. 2017; 8(50): 87244–62. doi: 10.18632/oncotarget.20244.

Lan C., Huang X., Lin S., Huang H., Cai Q., Wan T., Lu J., Liu J. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Tech Cancer Res Treat. 2013; 12(3): 259–67. doi: 10.7785/tcrt.2012.500312.

Medrek C., Pontén F., Jirström K., Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC cancer. 2012; 12: 306. doi: 10.1186/1471-2407-12-306.

Xu L., Zhu Y., Chen L., An H., Zhang W., Wang G., Lin Z., Xu J. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol. 2014; 21(9): 3142–50. doi: 10.1245/s10434-014-3601-1.

Zhang H., Wang X., Shen Z., Xu J., Qin J., Sun Y. Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer. 2015; 18(4): 740–50. doi: 10.1007/s10120-014-0422-7.

Zhang W.J., Wang X.H., Gao S.T., Chen C., Xu X.Y., Sun Q., Zhou Z.H., Wu G.Z., Yu Q., Xu G., Yao Y.Z., Guan W.X. Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. J Surg Res. 2018; 222: 93–101. doi: 10.1016/j.jss.2017.09.035.

Wang N., Liang H., Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol. 2014; 5: 614. doi: 10.3389/fimmu.2014.00614.

Juhas U., Ryba-Stanisławowska M., Szargiej P., Myśliwska J. Different pathways of macrophage activation and polarization. Postepy higieny i medycyny doswiadczalnej (Online). 2015; 69: 496–502. doi: 10.5604/17322693.1150133.

Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003; 3(1): 23–35. doi: 10.1038/nri978.

Szanto A., Balint B.L., Nagy Z.S., Barta E., Dezso B., Pap A., Szeles L., Poliska S., Oros M., Evans R.M., Barak Y., Schwabe J., Nagy L. STAT6 transcription factor is a facilitator of the nuclear receptor PPARγ-regulated gene expression in macrophages and dendritic cells. Immunity. 2010; 33(5): 699–712. doi: 10.1016/j.immuni.2010.11.009.

Takeda Y., Costa S., Delamarre E., Roncal C., Leite de Oliveira R., Squadrito M.L., Finisguerra V., Deschoemaeker S., Bruyère F., Wenes M., Hamm A., Serneels J., Magat J., Bhattacharyya T., Anisimov A., Jordan B.F., Alitalo K., Maxwell P., Gallez B., Zhuang Z.W., Saito Y., Simons M., De Palma M., Mazzone M. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature. 2011; 479(7371): 122–6. doi: 10.1038/nature10507.

Kang K., Reilly S.M., Karabacak V., Gangl M.R., Fitzgerald K., Hatano B., Lee C.H. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008; 7(6): 485–95. doi: 10.1016/j.cmet.2008.04.002.

Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Red Eagle A., Vats D., Brombacher F., Ferrante A.W., Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007; 447(7148): 1116–20. doi: 10.1038/nature05894.

Odegaard J.I., Ricardo-Gonzalez R.R., Red Eagle A., Vats D., Morel C.R., Goforth M.H., Subramanian V., Mukundan L., Ferrante A.W., Chawla A. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008; 7(6): 496–507. doi: 10.1016/j.cmet.2008.04.003.

Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23(11): 549–55. doi: 10.1016/s1471-4906(02)02302-5.

Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5): 1155–66. doi: 10.1172/jci31422.

Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G., Robinson S.C., Balkwill F.R. «Re-educating» tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008; 205(6): 1261–8. doi: 10.1084/jem.20080108.

Lawrence T., Gilroy D.W. Chronic inflammation: a failure of resolution? Int J Exp Pathol. 2007; 88(2): 85–94. doi: 10.1111/j.1365-2613.2006.00507.x.

Porta C., Rimoldi M., Raes G., Brys L., Ghezzi P., Di Liberto D., Dieli F., Ghisletti S., Natoli G., De Baetselier P., Mantovani A., Sica A. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci USA. 2009; 106(35): 14978–83. doi: 10.1073/pnas.0809784106.

Italiani P., Mazza E.M., Lucchesi D., Cifola I., Gemelli C., Grande A., Battaglia C., Bicciato S., Boraschi D. Transcriptomic profiling of the development of the inflammatory response in human monocytes in vitro. PloSone. 2014; 9(2): e87680. doi: 10.1371/journal.pone.0087680.

Raes G., De Baetselier P., Noël W., Beschin A., Brombacher F., Hassanzadeh Gh G. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukos Biol. 2002; 71(4): 597–602.

Netea-Maier R.T., Smit J.W.A., Netea M.G. Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship. Cancer Lett. 2018; 413: 102–9. doi: 10.1016/j.canlet.2017.10.037.

Freemerman A.J., Johnson A.R., Sacks G.N., Milner J.J., Kirk E.L., Troester M.A., Macintyre A.N., Goraksha-Hicks P., Rathmell J.C., Makowski L. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem. 2014; 289(11): 7884–96. doi: 10.1074/jbc.M113.522037.

Viola A., Munari F., Sánchez-Rodríguez R., Scolaro T., Castegna A. The Metabolic Signature of Macrophage Responses. Front Immunol. 2019; 10: 1462. doi: 10.3389/fimmu.2019.01462.

Palsson-McDermott E.M., Curtis A.M., Goel G., Lauterbach M.A., Sheedy F.J., Gleeson L.E., van den Bosch M.W., Quinn S.R., Domingo-Fernandez R., Johnston D.G., Jiang J.K., Israelsen W.J., Keane J., Thomas C., Clish C., Vander Heiden M., Xavier R.J., O'Neill L.A. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015; 21(1): 65–80. doi: 10.1016/j.cmet.2014.12.005.

Xie M., Yu Y., Kang R., Zhu S., Yang L., Zeng L., Sun X., Yang M., Billiar T.R., Wang H., Cao L., Jiang J., Tang D. PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation. Nature Commun. 2016; 7: 13280. doi: 10.1038/ncomms13280.

Nagy C., Haschemi A. Time and Demand are Two Critical Dimensions of Immunometabolism: The Process of Macrophage Activation and the Pentose Phosphate Pathway. Front Immunol. 2015; 6: 164. doi: 10.3389/fimmu.2015.00164.

Williams N.C., O'Neill L.A.J. A Role for the Krebs Cycle Intermediate Citrate in Metabolic Reprogramming in Innate Immunity and Inflammation. Front Immunol. 2018; 9: 141. doi: 10.3389/fimmu.2018.00141.

Infantino V., Convertini P., Cucci L., Panaro M.A., Di Noia M.A., Calvello R., Palmieri F., Iacobazzi V. The mitochondrial citrate carrier: a new player in inflammation. Biochem J. 2011; 438(3): 433–6. doi: 10.1042/bj20111275.

Van den Bossche J., O'Neill L.A., Menon D. Macrophage Immunometabolism: Where Are We (Going)? Trends Immunol. 2017; 38(6): 395–406. doi: 10.1016/j.it.2017.03.001.

Tannahill G.M., Curtis A.M., Adamik J., Palsson-McDermott E.M., McGettrick A.F., Goel G., Frezza C., Bernard N.J., Kelly B., Foley N.H., Zheng L., Gardet A., Tong Z., Jany S.S., Corr S.C., Haneklaus M., Caffrey B.E., Pierce K., Walmsley S., Beasley F.C., Cummins E., Nizet V., Whyte M., Taylor C.T., Lin H., Masters S.L., Gottlieb E., Kelly V.P., Clish C., Auron P.E., Xavier R.J., O'Neill L.A. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013; 496(7444): 238–42. doi: 10.1038/nature11986.

Choi J., Stradmann-Bellinghausen B., Yakubov E., Savaskan N.E., Régnier-Vigouroux A. Glioblastoma cells induce differential glutamatergic gene expressions in human tumor-associated microglia/macrophages and monocyte-derived macrophages. Cancer Biol Ther. 2015; 16(8): 1205–13. doi: 10.1080/15384047.2015.1056406.

Colegio O.R., Chu N.Q., Szabo A.L., Chu T., Rhebergen A.M., Jairam V., Cyrus N., Brokowski C.E., Eisenbarth S.C., Phillips G.M., Cline G.W., Phillips A.J., Medzhitov R. Functional polarization of tumourassociated macrophages by tumour-derived lactic acid. Nature. 2014; 513(7519): 559–63. doi: 10.1038/nature13490.

Palmieri E.M., Menga A., Martín-Pérez R., Quinto A., Riera-Domingo C., De Tullio G., Hooper D.C., Lamers W.H., Ghesquière B., McVicar D.W., Guarini A., Mazzone M., Castegna A. Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. Cell Rep. 2017; 20(7): 1654–66. doi: 10.1016/j.celrep.2017.07.054.

Moon J.S., Nakahira K., Chung K.P., DeNicola G.M., Koo M.J., Pabón M.A., Rooney K.T., Yoon J.H., Ryter S.W., Stout-Delgado H., Choi A.M. NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages. Nature Med. 2016; 22(9): 1002–12. doi: 10.1038/nm.4153.

Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M.T., Brickey W.J., Ting J.P. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature Immunol. 2011; 12(5): 408–15. doi: 10.1038/ni.2022.

Frigerio B., Bizzoni C., Jansen G., Leamon C.P., Peters G.J., Low P.S., Matherly L.H., Figini M. Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. J Exp Clin Cancer Res. 2019; 38(1): 125. doi: 10.1186/s13046-019-1123-1.

Shen J., Hu Y., Putt K.S., Singhal S., Han H., Visscher D.W., Murphy L.M., Low P.S. Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget. 2018; 9(4): 4485–95. doi: 10.18632/oncotarget.23321.

Puig-Kröger A., Sierra-Filardi E., Domínguez-Soto A., Samaniego R., Corcuera M.T., Gómez-Aguado F., Ratnam M., Sánchez-Mateos P., Corbí A.L. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 2009; 69(24): 9395–403. doi: 10.1158/0008-5472.can-09-2050.

Samaniego R., Palacios B.S., Domiguez-Soto Á., Vidal C., Salas A., Matsuyama T., Sánchez-Torres C., de la Torre I., Miranda-Carús M.E., Sánchez-Mateos P., Puig-Kröger A. Macrophage uptake and accumulation of folates are polarization-dependent in vitro and in vivo and are regulated by activin A. J Leukos Biol. 2014; 95(5): 797–808. doi: 10.1189/jlb.0613345.

Schmid M.C., Khan S.Q., Kaneda M.M., Pathria P., Shepard R., Louis T.L., Anand S., Woo G., Leem C., Faridi M.H., Geraghty T., Rajagopalan A., Gupta S., Ahmed M., Vazquez-Padron R.I., Cheresh D.A., Gupta V., Varner J.A. Integrin CD11b activation drives anti-tumor innate immunity. Nature Commun. 2018; 9(1): 5379. doi: 10.1038/s41467-018-07387-4.

Chistiakov D.A., Killingsworth M.C., Myasoedova V.A., Orekhov A.N., Bobryshev Y.V. CD68/macrosialin: not just a histochemical marker. Lab Invest. 2017; 97(1): 4–13. doi: 10.1038/labinvest.2016.116.

Khan S.Q., Khan I., Gupta V. CD11b Activity Modulates Pathogenesis of Lupus Nephritis. Front Med. 2018; 5. doi: 10.3389/fmed.2018.00052.

Helm O., Held-Feindt J., Schäfer H., Sebens S. M1 and M2: there is no «good» and «bad»-How macrophages promote malignancy-associated features in tumorigenesis. Oncoimmunology. 2014; 3(7): e946818. doi: 10.4161/21624011.2014.946818.

Ley K. M1 Means Kill; M2 Means Heal. J Immunol. 2017; 199(7): 2191–3. doi: 10.4049/jimmunol.1701135.

Mantovani A., Biswas S.K., Galdiero M.R., Sica A., Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013; 229(2): 176–85. doi: 10.1002/path.4133.

Tarique A.A., Logan J., Thomas E., Holt P.G., Sly P.D., Fantino E. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am J Resp Cell Mol Biol. 2015; 53(5): 676–88. doi: 10.1165/rcmb.2015-0012OC.

Saraiva D.P., Jacinto A., Borralho P., Braga S., Cabral M.G. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy. Front Immunol. 2018; 9. doi: 10.3389/fimmu.2018.02605.

Xue Q., Yan Y., Zhang R., Xiong H. Regulation of iNOS on Immune Cells and Its Role in Diseases. Int J Mol Sci. 2018; 19(12). doi: 10.3390/ijms19123805.

Soskic B., Jeffery L.E., Kennedy A., Gardner D.H., Hou T.Z., Halliday N., Williams C., Janman D., Rowshanravan B., Hirschfield G.M., Sansom D.M. CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis. Front Immunol. 2021; 11. doi: 10.3389/fimmu.2020.577655.

Devaraj S., Chen X., Adams-Huet B., Jialal I. Increased expression of Fc-γ receptors on monocytes in patients with nascent metabolic syndrome. J Clin Endocrinol Metab. 2013; 98(9): E1510-5. doi: 10.1210/jc.2013-2112.

Kzhyshkowska J., Mamidi S., Gratchev A., Kremmer E., Schmuttermaier C., Krusell L., Haus G., Utikal J., Schledzewski K., Scholtze J., Goerdt S. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood. 2006; 107(8): 3221–8. doi: 10.1182/blood-2005-07-2843.

Pouyafar A., Heydarabad M.Z., Mahboob S., Mokhtarzadeh A., Rahbarghazi R. Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed Pharmacother. 2018; 100: 478–85. doi: 10.1016/j.biopha.2018.02.050.

Rebelo S.P., Pinto C., Martins T.R., Harrer N., Estrada M.F., Loza-Alvarez P., Cabeçadas J., Alves P.M., Gualda E.J., Sommergruber W., Brito C. 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment. Biomaterials. 2018; 163: 185–97. doi: 10.1016/j.biomaterials.2018.02.030.

Tedesco S., Bolego C., Toniolo A., Nassi A., Fadini G.P., Locati M., Cignarella A. Phenotypic activation and pharmacological outcomes of spontaneously differentiated human monocyte-derived macrophages. Immunobiology. 2015; 220(5): 545–54. doi: 10.1016/j.imbio.2014.12.008.

Wang S., Zhang J., Sui L., Xu H., Piao Q., Liu Y., Qu X., Sun Y., Song L., Li D., Peng L., Hua S., Hu G., Chen J. Antibiotics induce polarization of pleural macrophages to M2-like phenotype in patients with tuberculous pleuritis. Sci Rep. 2017; 7(1): 14982. doi: 10.1038/s41598-017-14808-9.

Garton T., Keep R.F., Hua Y., Xi G. CD163, a Hemoglobin/Haptoglobin Scavenger Receptor, After Intracerebral Hemorrhage: Functions in Microglia/Macrophages Versus Neurons. Transl Stroke Res. 2017; 8(6): 612–6. doi: 10.1007/s12975-017-0535-5.

Barros M.H., Hauck F., Dreyer J.H., Kempkes B., Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PloSone. 2013; 8(11): e80908. doi: 10.1371/journal.pone.0080908.

Tsuchiya K., Suzuki Y., Yoshimura K., Yasui H., Karayama M., Hozumi H., Furuhashi K., Enomoto N., Fujisawa T., Nakamura Y., Inui N., Yokomura K., Suda T. Author Correction: Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia. Sci Rep. 2020; 10(1): 3324. doi: 10.1038/s41598-020-58958-9.

Komohara Y., Jinushi M., Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014; 105(1): 1–8. doi: 10.1111/cas.12314.

Jing J., Yang I.V., Hui L., Patel J.A., Evans C.M., Prikeris R., Kobzik L., O'Connor B.P., Schwartz D.A. Role of macrophage receptor with collagenous structure in innate immune tolerance. J Immunol. 2013; 190(12): 6360–7. doi: 10.4049/jimmunol.1202942.

McMillan S.J., Kearley J., Campbell J.D., Zhu X.W., Larbi K.Y., Shipley J.M., Senior R.M., Nourshargh S., Lloyd C.M. Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J Immunol. 2004; 172(4): 2586–94. doi: 10.4049/jimmunol.172.4.2586.

Chávez-Galán L., Olleros M.L., Vesin D., Garcia I. Much More than M1 and M2 Macrophages, There are also CD169(+) and TCR(+) Macrophages. Front Immunol. 2015; 6: 263. doi: 10.3389/fimmu.2015.00263.

Liu T., Larionova I., Litviakov N., Riabov V., Zavyalova M., Tsyganov M., Buldakov M., Song B., Moganti K., Kazantseva P., Slonimskaya E., Kremmer E., Flatley A., Klüter H., Cherdyntseva N., Kzhyshkowska J. Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy. Oncoimmunology. 2018; 7(6): e1436922. doi: 10.1080/2162402x.2018.1436922.

Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., Waldvogel B., Vannier C., Darling D., zur Hausen A., Brunton V.G., Morton J., Sansom O., Schüler J., Stemmler M.P., Herzberger C., Hopt U., Keck T., Brabletz S., Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biol. 2009; 11(12): 1487–95. doi: 10.1038/ncb1998.

Hill L., Browne G., Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer. 2013; 132(4): 745–54. doi: 10.1002/ijc.27708.

Stoermer K.A., Burrack A., Oko L., Montgomery S.A., Borst L.B., Gill R.G., Morrison T.E. Genetic ablation of arginase 1 in macrophages and neutrophils enhances clearance of an arthritogenic alphavirus. J Immunol. 2012; 189(8): 4047–59. doi: 10.4049/jimmunol.1201240.

Kalia N., Singh J., Kaur M. The role of dectin-1 in health and disease. Immunobiology. 2021; 226(2): 152071. doi: 10.1016/j.imbio.2021.152071.

Arango Duque G., Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014; 5: 491. doi: 10.3389/fimmu.2014.00491.

Atri C., Guerfali F.Z., Laouini D. Role of Human Macrophage Polarization in Inflammation during Infectious Diseases. Int J Mol Sci. 2018; 19(6). doi: 10.3390/ijms19061801.

Zheng X., Turkowski K., Mora J., Brüne B., Seeger W., Weigert A., Savai R. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 2017; 8(29): 48436–52. doi: 10.18632/oncotarget.17061.

Turner M.D., Nedjai B., Hurst T., Pennington D.J. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta. 2014; 1843(11): 2563–82. doi: 10.1016/j.bbamcr.2014.05.014.

Verreck F.A., de Boer T., Langenberg D.M., van der Zanden L., Ottenhoff T.H. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukos Biol. 2006; 79(2): 285–93. doi: 10.1189/jlb.0105015.

Wicks I.P., Roberts A.W. Targeting GM-CSF in inflammatory diseases. Nature Rev Rheumatol. 2016; 12(1): 37–48. doi: 10.1038/nrrheum.2015.161.

Stanley E.R., Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Rerspect Biol. 2014; 6(6). doi: 10.1101/cshperspect.a021857.

Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nature Rev Immunol. 2008; 8(7): 533–44. doi: 10.1038/nri2356.

Lacey D.C., Achuthan A., Fleetwood A.J., Dinh H., Roiniotis J., Scholz G.M., Chang M.W., Beckman S.K., Cook A.D., Hamilton J.A. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol. 2012; 188(11): 5752–65. doi: 10.4049/jimmunol.1103426.

Ushach I., Zlotnik A. Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage. J Leukoc Biol. 2016; 100(3): 481–9. doi: https://doi.org/10.1189/jlb.3RU0316-144R.

Müller E., Christopoulos P.F., Halder S., Lunde A., Beraki K., Speth M., Øynebråten I., Corthay A. Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages. Front Immunol. 2017; 8: 1383. doi: 10.3389/fimmu.2017.01383.

Wang C.Q.F., Suárez-Fariñas M., Nograles K.E., Mimoso C.A., Shrom D., Dow E.R., Heffernan M.P., Hoffman R.W., Krueger J.G. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol. 2014; 134(12): 2990–3. doi: 10.1038/jid.2014.268.

Netea M.G., Lewis E.C., Azam T., Joosten L.A., Jaekal J., Bae S.Y., Dinarello C.A., Kim S.H. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA. 2008; 105(9): 3515–20. doi: 10.1073/pnas.0712381105.

Domschke G., Gleissner C.A. CXCL4-induced macrophages in human atherosclerosis. Cytokine. 2019; 122: 154141. doi: 10.1016/j.cyto.2017.08.021.

Gleissner C.A., Shaked I., Little K.M., Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol. 2010; 184(9): 4810–8. doi: 10.4049/jimmunol.0901368.

Sierra-Filardi E., Nieto C., Domínguez-Soto A., Barroso R., Sánchez-Mateos P., Puig-Kroger A., López-Bravo M., Joven J., Ardavín C., Rodríguez-Fernández J.L., Sánchez-Torres C., Mellado M., Corbí A.L. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J Immunol. 2014; 192(8): 3858–67. doi: 10.4049/jimmunol.1302821.

Roca H., Varsos Z.S., Sud S., Craig M.J., Ying C., Pienta K.J. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009; 284(49): 34342–54. doi: 10.1074/jbc.M109.042671.

Farmaki E., Kaza V., Chatzistamou I., Kiaris H. CCL8 Promotes Postpartum Breast Cancer by Recruiting M2 Macrophages. iScience. 2020; 23(6): 101217. doi: 10.1016/j.isci.2020.101217.

Fu X.L., Duan W., Su C.Y., Mao F.Y., Lv Y.P., Teng Y.S., Yu P.W., Zhuang Y., Zhao Y.L. Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression. Cancer Immunol Immunother. 2017; 66(12): 1597–608. doi: 10.1007/s00262-017-2052-5.

Masteller E.L., Wong B.R. Targeting IL-34 in chronic inflammation. Drug Discovery Today. 2014; 19(8): 1212–6. doi: 10.1016/j.drudis.2014.05.016.

Boulakirba S., Pfeifer A., Mhaidly R., Obba S., Goulard M., Schmitt T., Chaintreuil P., Calleja A., Furstoss N., Orange F., Lacas-Gervais S., Boyer L., Marchetti S., Verhoeyen E., Luciano F., Robert G., Auberger P., Jacquel A. IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential. Sci Rep. 2018; 8(1): 256. doi: 10.1038/s41598-017-18433-4.

Baghdadi M., Wada H., Nakanishi S., Abe H., Han N., Putra W.E., Endo D., Watari H., Sakuragi N., Hida Y., Kaga K., Miyagi Y., Yokose T., Takano A., Daigo Y., Seino K.I. Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells. Cancer Res. 2016; 76(20): 6030–42. doi: 10.1158/0008-5472.can-16-1170.

Oishi Y., Manabe I. Integrated regulation of the cellular metabolism and function of immune cells in adipose tissue. Clin Exp Pharmacol Physiol. 2016; 43(3): 294–303. doi: 10.1111/1440-1681.12539.

O'Neill L.A., Kishton R.J., Rathmell J. A guide to immunometabolism for immunologists. Nature Rev Immunol. 2016; 16(9): 553–65. doi: 10.1038/nri.2016.70.

Staples K.J., Sotoodehnejadnematalahi F., Pearson H., Frankenberger M., Francescut L., Ziegler-Heitbrock L., Burke B. Monocyte-derived macrophages matured under prolonged hypoxia transcriptionally up-regulate HIF-1α mRNA. Immunobiology. 2011; 216(7): 832–9. doi: 10.1016/j.imbio.2010.12.005.

Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004; 25(6): 280–8. doi: 10.1016/j.it.2004.03.008.

Hoeksema M.A., de Winther M.P. Epigenetic Regulation of Monocyte and Macrophage Function. Antioxid Redox Signal. 2016; 25(14): 758–74. doi: 10.1089/ars.2016.6695.

100

Davis F.M., Gallagher K.A. Epigenetic Mechanisms in Monocytes/Macrophages Regulate Inflammation in Cardiometabolic and Vascular Disease. Arterioscler Thromb Vasc Biol. 2019; 39(4): 623–34. doi: 10.1161/atvbaha.118.312135.

101

Holliday R., Pugh J.E. DNA modification mechanisms and gene activity during development. Science. 1975; 187(4173): 226–32.

102

Yang X., Wang X., Liu D., Yu L., Xue B., Shi H. Epigenetic regulation of macrophage polarization by DNA methyltransferase 3b. Mol Endocrinol. 2014; 28(4): 565–74. doi: 10.1210/me.2013-1293.

103

Cheng C., Huang C., Ma T.T., Bian E.B., He Y., Zhang L., Li J. SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages. Toxicol Lett. 2014; 225(3): 488–97. doi: 10.1016/j.toxlet.2013.12.023.

104

Larionova I., Kazakova E., Patysheva M., Kzhyshkowska J. Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages. Cancers. 2020; 12(6). doi: 10.3390/cancers12061411.

105

Van den Bossche J., Neele A.E., Hoeksema M.A., de Winther M.P. Macrophage polarization: the epigenetic point of view. Curr Opin Lipidol. 2014; 25(5): 367–73. doi: 10.1097/mol.0000000000000109.

106

Kittan N.A., Allen R.M., Dhaliwal A., Cavassani K.A., Schaller M., Gallagher K.A., Carson W.F.t., Mukherjee S., Grembecka J., Cierpicki T., Jarai G., Westwick J., Kunkel S.L., Hogaboam C.M. Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PloSone. 2013; 8(10): e78045. doi: 10.1371/journal.pone.0078045.

107

Satoh T., Takeuchi O., Vandenbon A., Yasuda K., Tanaka Y., Kumagai Y., Miyake T., Matsushita K., Okazaki T., Saitoh T., Honma K., Matsuyama T., Yui K., Tsujimura T., Standley D.M., Nakanishi K., Nakai K., Akira S. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. 2010; 11(10): 936–44. doi: 10.1038/ni.1920.

108

Feng D., Sangster-Guity N., Stone R., Korczeniewska J., Mancl M.E., Fitzgerald-Bocarsly P., Barnes B.J. Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J Immunol. 2010; 185(10): 6003–12. doi: 10.4049/jimmunol.1000482.

109

Leus N.G., Zwinderman M.R., Dekker F.J. Histone deacetylase-3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation. Curr Opin Chem Biol. 2016; 33: 160–8. doi: 10.1016/j.cbpa.2016.06.019.

110

Mullican S.E., Gaddis C.A., Alenghat T., Nair M.G., Giacomin P.R., Everett L.J., Feng D., Steger D.J., Schug J., Artis D., Lazar M.A. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev. 2011; 25(23): 2480–8. doi: 10.1101/gad.175950.111.

111

Graff J.W., Dickson A.M., Clay G., McCaffrey A.P., Wilson M.E. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem. 2012; 287(26): 21816–25. doi: 10.1074/jbc.M111.327031.

112

Cai X., Yin Y., Li N., Zhu D., Zhang J., Zhang C.-Y., Zen K. Repolarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol. 2012; 4(5): 341–3. doi: 10.1093/jmcb/mjs044.

113

Martinez-Nunez R.T., Louafi F., Sanchez-Elsner T. The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J Biol Chem. 2011; 286(3): 1786–94. doi: 10.1074/jbc.M110.169367.

114

Litvak V., Ramsey S.A., Rust A.G., Zak D.E., Kennedy K.A., Lampano A.E., Nykter M., Shmulevich I., Aderem A. Function of C/EBPδ in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat Immunol. 2009; 10(4): 437–43. doi: 10.1038/ni.1721.

115

Lu T., Yang X., Huang Y., Zhao M., Li M., Ma K., Yin J., Zhan C., Wang Q. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019; 11: 943–53. doi: 10.2147/cmar.s187317.

116

Millrud C.R., Mehmeti M., Leandersson K. Docetaxel promotes the generation of anti-tumorigenic human macrophages. Exp Cell Res. 2018; 362(2): 525–31. doi: 10.1016/j.yexcr.2017.12.018.

117

Shree T., Olson O.C., Elie B.T., Kester J.C., Garfall A.L., Simpson K., Bell-McGuinn K.M., Zabor E.C., Brogi E., Joyce J.A. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011; 25(23): 2465–79. doi: 10.1101/gad.180331.111.

118

Bryniarski K., Szczepanik M., Ptak M., Zemelka M., Ptak W. Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. Pharmacol Rep. 2009; 61(3): 550–7. doi: 10.1016/s1734-1140(09)70098-2.

119

Hughes R., Qian B.Z., Rowan C., Muthana M., Keklikoglou I., Olson O.C., Tazzyman S., Danson S., Addison C., Clemons M., Gonzalez-Angulo A.M., Joyce J.A., De Palma M., Pollard J.W., Lewis C.E. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res. 2015; 75(17): 3479–91. doi: 10.1158/0008-5472.can-14-3587.

The authors declare that there are no conflicts of interest present.